The Current Landscape of Marijuana and Pharmacogenetics
- PMID: 28975060
- PMCID: PMC5621775
- DOI: 10.7759/cureus.1525
The Current Landscape of Marijuana and Pharmacogenetics
Abstract
The treatment of medical conditions with cannabis and cannabinoid compounds is advancing. Although there are numerous reports related to the genetic variations of the cannabinoid receptor, a lack of studies that examine the relationship between other pharmacogenetic markers and health outcomes currently exists. Herein, we advocate for the legalization of marijuana in the United States in order to perform more randomized controlled trials to help elucidate the role of other pharmacogenetic targets and cannabis for use in clinical practice.
Keywords: cannabis; genetics; marijuana; marijuana legalization; medical marijuana; pharmacogenetics.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
References
-
- Cannabinoid-opioid interaction in chronic pain. Abrams DI, Couey P, Shade SB, et al. Clin Pharmacol Ther. 2011;90:844–851. - PubMed
-
- Cannabis reduces opioid dose in the treatment of chronic non-cancer pain. Lynch ME, Clark AJ. J Pain Symptom Manage. 2003;25:496–498. - PubMed
-
- Medical marijuana laws reduce prescription medication use in Medicare Part D. Bradford AC, Bradford WD. Health Aff (Millwood) 2016;35:1230–1236. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources